CoChat

CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study

Open access
Wilson, Darrell M., Pietropaolo, Susan L., Acevedo-Calado, Maria, Huang, Shuai, Anyaiwe, Destiny, Scheinker, David, Steck, Andrea K., Vasudevan, Madhuri M., McKay, Siripoom V., Sherr, Jennifer L., Herold, Kevan C., Dunne, Jessica L., Greenbaum, Carla J., Lord, Sandra M., Haller, Michael J., Schatz, Desmond A., Atkinson, Mark A., Nelson, Patrick W., Pietropaolo, Massimo, the Type 1 Diabetes TrialNet Study Group · 2023 · Diabetes Care
Cited by 56

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Continuous glucose monitoring (CGM) parameters may identify individuals at risk for progression to overt type 1 diabetes. We aimed to determine whether CGM metrics provide additional insights into progression to clinical stage 3 type 1 diabetes. RESEARCH DESIGN AND METHODS: One hundred five relatives of individuals in type 1 diabetes probands (median age 16.8 years; 89% non-Hispanic White; 43.8% female) from the TrialNet Pathway to Prevention study underwent 7-day CGM assessments and oral glucose tolerance tests (OGTTs) at 6-month intervals. The baseline data are reported here. Three groups were evaluated: individuals with 1) stage 2 type 1 diabetes (n = 42) with two or more diabetes-related autoantibodies and abnormal OGTT; 2) stage 1 type 1 diabetes (n = 53) with two or more diabetes-related autoantibodies and normal OGTT; and 3) negative test for all diabetes-related autoantibodies and normal OGTT (n = 10). RESULTS: Multiple CGM metrics were associated with progression to stage 3 type 1 diabetes. Specifically, spending ≥5% time with glucose levels ≥140 mg/dL (P = 0.01), ≥8% time with glucose levels ≥140 mg/dL (P = 0.02), ≥5% time with glucose levels ≥160 mg/dL (P = 0.0001), and ≥8% time with glucose levels ≥160 mg/dL (P = 0.02) were all associated with progression to stage 3 disease. Stage 2 participants and those who progressed to stage 3 also exhibited higher mean daytime glucose values; spent more time with glucose values over 120, 140, and 160 mg/dL; and had greater variability. CONCLUSIONS: CGM could aid in the identification of individuals, including those with a normal OGTT, who are likely to rapidly progress to stage 3 type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc22-1297

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 56

Metadata

Authors
Wilson, D. M., Pietropaolo, S. L., Acevedo-Calado, M., Huang, S., Anyaiwe, D., Scheinker, D., Steck, A. K., Vasudevan, M. M., McKay, S. V., Sherr, J. L., Herold, K. C., Dunne, J. L., Greenbaum, C. J., Lord, S. M., Haller, M. J., Schatz, D. A., Atkinson, M. A., Nelson, P. W., Pietropaolo, M., & the Type 1 Diabetes TrialNet Study Group
Venue
Diabetes Care
Published
2023-02-02
Volume
46
Issue
3
Pages
526-534
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W4318960207
Cited by
56
References
12
FWCI
8.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. https://app.cochat.ai/papers/10.2337/dc22-1297
The paper
Wilson, D. M., Pietropaolo, S. L., Acevedo-Calado, M., Huang, S., Anyaiwe, D., Scheinker, D., Steck, A. K., Vasudevan, M. M., McKay, S. V., Sherr, J. L., Herold, K. C., Dunne, J. L., Greenbaum, C. J., Lord, S. M., Haller, M. J., Schatz, D. A., Atkinson, M. A., Nelson, P. W., Pietropaolo, M., & the Type 1 Diabetes TrialNet Study Group. (2023). CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care. https://doi.org/10.2337/dc22-1297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.